58 completed, 9 terminated, 5 recruiting, 4 active not recruiting. 81 Phase 2, 9 Phase 1, 8 Phase 3.
Follow Hypertriglyceridemia: new trials by email Literature Review of Hypertriglyceridemia trials Research Report on Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease DR10624 Injection, Placebo - Hypertriglyceridemia | Phase 2 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 315 | 2026-10-01 | 2026-09-30 |
| A Study to Assess the Safety, Tolerability and Efficacy of ION775 ION775 - Hypertriglyceridemia, Severe Hypertriglyceridemia | Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 72 | 2026-05-12 | 2026-11-02 |
| RBD5044 in Chinese Participants With Hypertriglyceridemia RBD5044, Placebo - Hypertriglyceridemia | Phase 2 | Active not recruiting | Ribotek Biopharmaceuticals (Shandong) Co., Ltd | 40 | 2026-02-28 | 2026-08-24 |
| A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia Solbinsiran, Placebo - Severe Hypertriglyceridemia | Phase 2 | Recruiting | Eli Lilly and Company | 60 | 2025-12-08 | 2026-11-04 |
| A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol MAR001, Placebo - Hypertriglyceridemia | Phase 2 | Recruiting | Marea Therapeutics | 30 | 2025-09-26 | 2025-11-06 |
| a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia JMT202 injection, Placebo - Hypertriglyceridemia | Phase 1 / Phase 2 | Recruiting | Shanghai JMT-Bio Inc. | 48 | 2025-09-09 | 2025-12-30 |
| Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol MAR001, Placebo - Hypertriglyceridemia | Phase 2 | Recruiting | Marea Therapeutics | 316 | 2025-06-30 | 2026-09-02 |
| Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects RN0361 - Hypertriglyceridemia, Familial Chylomicronemia Syndrome | Phase 1 / Phase 2 | Active not recruiting | Ikaria Bioscience Pty Ltd | 108 | 2024-09-30 | 2025-12-30 |
| Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD TLC-2716 Dose 1, TLC-2716 Dose 2, Placebo - Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease | Phase 2 | Unknown | OrsoBio, Inc | 30 | 2024-08-12 | 2025-04-03 |
| A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia DR10624 Injection, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | Zhejiang Doer Biologics Co., Ltd. | 79 | 2024-08-01 | 2026-01-13 |
| Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women Phytoestrogen, Diet control & life style modification - Dyslipidemias, Hypertriglyceridemia | Phase 2 / Phase 3 | Unknown | Dhurakij Pundit University | 10 | 2024-03-02 | 2024-05-24 |
| Study of MAR001 in Adults With Metabolic Dysfunction MAR001, Placebo - Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Marea Therapeutics | 55 | 2023-07-22 | 2025-11-13 |
| Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia NST-1024, Placebo - High Triglycerides | Phase 2 | Completed | NorthSea Therapeutics B.V. | 50 | 2023-06-30 | 2025-04-24 |
| MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia MN-001, MN-001 placebo - Diabetes Mellitus, Type 2, Hypertriglyceridemia | Phase 2 | Active not recruiting | MediciNova | 40 | 2022-08-22 | 2026-02-05 |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 154 | 2022-05-09 | 2026-04-23 |
| Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis evinacumab, Placebo - Hypertriglyceridemia | Phase 2 | Terminated | Regeneron Pharmaceuticals | 21 | 2021-07-12 | 2024-05-22 |
| Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia ARO-APOC3, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | Arrowhead Pharmaceuticals | 229 | 2021-05-31 | 2026-03-24 |
| Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes DS102, Placebo - Hypertriglyceridemia, Type 2 Diabetes | Phase 2 | Terminated | Afimmune | 233 | 2020-10-13 | 2023-06-12 |
| Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | 89bio, Inc. | 86 | 2020-09-01 | 2024-07-25 |
| Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia Omega 3 pentaenoic acid, icosapent ethyl - Hypertriglyceridemia | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 100 | 2020-06-03 | 2022-03-04 |
Showing 20 of 81. Sign in to see all of them.
Dyslipidemias (12) · Hypercholesterolemia (10) · Hyperlipidemias (8) · Non-alcoholic Fatty Liver Disease (8) · Diabetes Mellitus (6) · Lipid Metabolism Disorders (5) · Lipodystrophy (5) · Diabetes Mellitus, Type 2 (4) · Metabolic Diseases (4) · Hyperlipoproteinemia Type I (3) · Insulin Resistance (3) · Metabolic Syndrome (3) · Cardiovascular Diseases (2) · Familial hyperchylomicronemia syndrome (2)
Nutritional and Metabolic Diseases (81) · Metabolic Diseases (77) · Lipid Metabolism Disorders (76) · Hyperlipidemias (73) · Dyslipidemias (69) · Glucose Metabolism Disorders (12) · Digestive System Diseases (8) · Endocrine System Diseases (8) · Liver Diseases (7) · Pathological Conditions, Signs and Symptoms (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Fatty Liver (6) · Genetic Diseases, Inborn (6) · Lipid Metabolism, Inborn Errors (6) · Skin Diseases (6)
Fenofibrate (9) · Omacor (5) · metreleptin (4) · pradigastat (4) · Fish Oils (3) · gemcabene (3) · 4-(6-acetyl-3-(3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy)-2-propylphenoxy)butyric acid (2) · 6-(4'-trifluoromethyl-6-methoxybiphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester (2) · Corn Oil (2) · MAT9001 (2) · Metformin (2) · Orlistat (2) · eicosapentaenoic acid ethyl ester (2) · evinacumab (2) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · Novartis Pharmaceuticals (4) · AstraZeneca (3) · Catabasis Pharmaceuticals (3) · Ionis Pharmaceuticals, Inc. (3) · Marea Therapeutics (3) · Akcea Therapeutics (2) · Essentialis, Inc. (2) · Grace Therapeutics Inc. (2) · MediciNova (2) · NeuroBo Pharmaceuticals Inc. (2) · Regeneron Pharmaceuticals (2) · The Hospital for Sick Children (2) · University of Pennsylvania (2) · University of Texas Southwestern Medical Center (2)
United States (51) · Canada (27) · China (5) · Netherlands (5) · Australia (4) · Germany (4) · Hungary (4) · Norway (3) · Poland (3) · Sweden (3) · France (2) · India (2) · Italy (2) · New Zealand (2) · Russia (2)
Rebecca J Brown, M.D. (3) · Abhimanyu Garg, MD (2) · Jean-Claude Tardif, MD (2) · Alain Baron, M.D. (1) · Alan Forker, MD (1) · Alex DePaoli (1) · Andrew Lewin, MD (1) · Angel Brea, MD (1) · Ari Bitnun, MD, MSc (1) · Brad West, ND (1)
PMID 28324110, PMID 31194872, PMID 34677608, PMID 34223895, PMID 17971707, PMID 19727665, PMID 21518985, PMID 21982664, PMID 22068254, PMID 22965160, PMID 23312053, PMID 24528690, PMID 24926953, PMID 25070319, PMID 25084280, PMID 25393536, PMID 25670366, PMID 25734254, PMID 25889044, PMID 26222559, PMID 26589105, PMID 26691888, PMID 26900642, PMID 28391875, PMID 29659879, PMID 29723161, PMID 30197273, PMID 32191645, PMID 32573497, PMID 33890058, PMID 35025993, PMID 35232215, PMID 35291351, PMID 36195542, PMID 36879129, PMID 37355760, PMID 37515588, PMID 37595266, PMID 38583092, PMID 38587249, PMID 40258408, PMID 40383129, PMID 42753678, PMID 42838769
2016 (1), R01DK088114 (1)